Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny (PGNY) filed a Form 144 notifying a proposed sale of 2,500 shares of its common stock, with an aggregate market value of $55,087.50, through Fidelity Brokerage Services LLC on 08/11/2025. The shares were acquired on 10/24/2021 via restricted stock vesting and were granted as compensation; the filer reports no securities sold in the past three months.
The filing includes the issuer's outstanding share count of 85,982,409, making the proposed sale a very small fraction of outstanding stock. The notice includes the filer’s representation that no undisclosed material adverse information about the issuer is known.
Progyny (PGNY) filed its Q2-25 10-Q showing solid top-line momentum and margin expansion, tempered by higher opex and tax expense.
- Revenue rose 9.5% YoY to $332.9 m; pharmacy contributed 36% while core fertility benefits grew 10.5%. 1H-25 revenue is up 12.9% to $656.9 m.
- Gross profit improved 15.7% to $79.0 m; gross margin expanded 130 bp to 23.7% as case-rate pricing and pharmacy rebates offset service-cost inflation.
- Operating income increased 17.7% to $24.4 m; however, a higher effective tax rate (36.8% vs 34.2%) limited net income growth to 3.8% ($17.1 m, $0.19 diluted EPS).
- For 1H-25, net income slipped 3.6% to $32.2 m, but diluted EPS rose to $0.36 on a 10% lower share count following 2024 buybacks.
- Cash & M-secs stand at $305.1 m, up $18.1 m YoY; operating cash flow strengthened 28% to $105.3 m. No debt; a new $200 m undrawn revolver was signed 1 Jul 25.
- Balance sheet: current ratio 2.7x; equity climbed 22% to $515.0 m. Accounts receivable (+16%) and payables (+48%) rose with volume.
- Operations: ART cycles grew 8.8% to 16,938 while overall member utilization held at 0.55%. Client count reached 542 covering 6.8 m lives.
- M&A: closed $10.5 m Benefit Bump acquisition in Jan-25; integration ongoing.
Overall, PGNY continues to outpace the fertility-benefits market, generating healthy cash and maintaining a debt-free profile, though investors should watch rising opex, receivables exposure and tax headwinds.